



Indonesia

Financial Reporting



The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rounding differences in the numbers presented may occur.

Viartis collaboration
for selatogrel and
cenerimod

Restructured
convertible bond –
extending cash
runway

Adapted governance
structure



Highlights of H1 2024


Approval of
aprocitentan
TRYVIO in the US
JERAYGO in the EU

QUVIVIQ NDA
submitted in
Greater China by
Simcere

Vaccine for
Clostridium Difficile
advanced into Phase 1




Extend the cash runway



**What needs
to be done in
H2 2024**



**Continue to increase
sales of QUVIVIQ**



**Prepare for the launch
of TRYVIO in the US**




Continue to innovate

US sales outpaces field force changes




US net sales

CHF million




QUVIVIQ field force



Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK, Canada, Austria, and France under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union.

TRYVIO US launch on track




Aprocitentan is only approved in the US under the tradename TRYVIO™ where it will be made available later in 2024, and in Europe under the tradename JERAYGO™. Market authorization is under review in other countries.




EUCAN net sales growth

CHF million



Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK, Canada, Austria, and France under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union.

EUCAN reimbursement status




OOP = Out of pocket

Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK, Canada, Austria, and France under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union.

Non-GAAP operating results

in CHF millions, rounding differences may occur



¹ excluding the business sold as part of the Nxera deal

Financial results as of June 30, 2024

HY 2024 vs 2023 operating performance

HY 2024 performance as reported

CHF million	Idorsia business	Partnered business	Global Business
REVENUE	24	3	26
COGS	-4	–	-4
SG&A OPEX	-134	–	-134
R&D OPEX	-61	–	-61
Other	3	–	3
Non-GAAP EBIT	-173	3	-170
D&A	-8	–	-8
SBC	-10	–	-10
Other	-1	125	124
US-GAAP EBIT	-192	128	-64


HY 2023 performance proforma¹

Idorsia business	Partnered business	Global Business
12	6	19
-2	–	-2
-216	–	-216
-146	–	-146
–	–	–
-350	6	-346
-7	–	-7
-24	–	-24
–	–	–
-381	6	-376

¹ excluding the business sold as part of the Nxera deal

HY 2024 cash development

in CHF millions, rounding differences may occur



Financial outlook

CHF million	Guidance for 2024		
	Idorsia business	Partnered business	Global Business
REVENUE	55	15	70
COGS	-10	-10	-20
SG&A OPEX	-300	–	-300
R&D OPEX	-145	0	-145
Non-GAAP EBIT	-400	5	-395
D&A	-15	–	-15
SBC	-35	–	-35
Other	–	125	125
US-GAAP EBIT	-450	130	-320

Excluding unforeseen events



More
questions?

